


PHARMACEUTICAL 2023



PUMA BIOTECHNOLOGY INC. Rank 274 of 446





PHARMACEUTICAL 2023



PUMA BIOTECHNOLOGY INC. Rank 274 of 446

The relative strengths and weaknesses of PUMA BIOTECHNOLOGY INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA BIOTECHNOLOGY INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 102% points. The greatest weakness of PUMA BIOTECHNOLOGY INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is 29%, being 15% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	134,281
Cost of Goods Sold	55,093
Intangible Assets	0
Liabilities, Current	77,484
Liabilities, Non-Current	110,141
Other Assets	86,632
Other Compr. Net Income	2.0
Other Expenses	7,455
Other Liabilities	12,826
Other Net Income	0
Other Revenues	228,031
Property and Equipment	1,146
Research and Development	52,240
Selling, General and Administrative Expense	89,978

Output Variable	Value in 1000 USD
Assets	222,059
Liabilities	200,451
Expenses	204,766
Revenues	228,031
Stockholders Equity	21,608
Net Income	23,265
Comprehensive Net Income	23,266
Economic Capital Ratio	29%

